HealthyPhase 1NCT07297940
Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State
A Phase 1 study testing DA-1229_01 and DA-1229_01-R in people with Healthy, run by Dong-A ST Co., Ltd. at 1 site in South Korea.
Trial summary
This clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 at fasting state. Read more about this study
- Who is it for?
- Ages 19 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- DA-1229_01 and DA-1229_01-R
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 1 siteSouth Korea
- Study dates
- 14 Dec 2025to 31 Jan 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy volunteers
- BMI between 18 and 30 kg/m2
- Body weight: Male ≥ 50kg, Female ≥ 45kg
- Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study
Who cannot join
- Subjects with clinically significant medical history
- Subjects with history of drug abuse or addicted
- Subjects with allergy or drug hypersensitivity
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 in Healthy Subjects at Fasting State
This clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 at fasting state.
- Conditions
- Healthy
- Being tested
- DA-1229_01, DA-1229_01-R
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DA-1229_01Drug
single dose administration (DA-1229 one tablet once a day)
DA-1229_01-RDrug
single dose administration (DA-1229_01-R one tablet once a day)
| Study group | Role | What they receive |
|---|---|---|
| Sequence A | Experimental | Not described Receives: Drug: DA-1229_01; Drug: DA-1229_01-R |
| Sequence B | Experimental | Not described Receives: Drug: DA-1229_01; Drug: DA-1229_01-R |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUCt
Area Under the Curve
Measured: pre-dose~72 hours post-dose
Cmax
Maximum Plasma Concentration
Measured: pre-dose~72 hours post-dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Dec 2025
- Study start14 Dec 2025
- Primary completion31 Jan 2026
- Study completion31 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dong-A ST Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07297940
- Sponsor's protocol ID
- DA1229_01-M_Fast_BE
- Status last verified
- Mar 2026
- First submitted
- 9 Dec 2025
- Last updated
- 31 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 in Healthy Subjects at Fasting State
- ClinicalTrials.gov ID
- NCT07297940
- Acronym / sponsor ID
- DA1229_01-M_Fast_BE
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Dong-A ST Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 14 Dec 2025 (actual)
- Primary completion
- 31 Jan 2026 (actual)
- Study completion
- 31 Jan 2026 (actual)
- First posted
- 22 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 at fasting state.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sequence A | Experimental | Drug: DA-1229_01, Drug: DA-1229_01-R |
| Sequence B | Experimental | Drug: DA-1229_01, Drug: DA-1229_01-R |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Healthy volunteers
- BMI between 18 and 30 kg/m2
- Body weight: Male ≥ 50kg, Female ≥ 45kg
- Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study
Key exclusion criteria (3 listed)
- Subjects with clinically significant medical history
- Subjects with history of drug abuse or addicted
- Subjects with allergy or drug hypersensitivity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DA-1229_01single dose administration (DA-1229 one tablet once a day) | Drug | Sequence A, Sequence B |
| DA-1229_01-Rsingle dose administration (DA-1229_01-R one tablet once a day) | Drug | Sequence A, Sequence B |
Primary outcome
AUCt
Time frame: pre-dose~72 hours post-dose
Area Under the Curve
Cmax
Time frame: pre-dose~72 hours post-dose
Maximum Plasma Concentration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2026.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing DA-1229_01 and DA-1229_01-R in people with Healthy, run by Dong-A ST Co., Ltd. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AUCt (time frame: pre-dose~72 hours post-dose). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.